Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Roshini Claire Anthony, 19 Sep 2016

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.

01 Apr 2016
New drug applications approved by US FDA as of 16 - 31 Mar 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Apr 2015
New drug applications approved by US FDA as of 1 – 15 April 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

More emphasis necessary for TB prevention in paediatric population

Pank Jit Sin
04 Aug 2017

A documented household exposure should trigger prompt contact tracing to allow timely diagnosis and to prevent the development of tuberculosis (TB) disease, according to a specialist.

The treatment of latent TB infection (LTBI) in children is fairly safe and effective. Adverse events are relatively uncommon; the most common side effects include nausea and vomiting, said infectious diseases and paediatric consultant Dr. Tan Kah Kee, who was speaking at the Malaysian Thoracic Society (MTS) Annual Congress 2017, held in Kuala Lumpur recently. It is important to educate caregivers to monitor these symptoms, and to assess the child’s clinical symptoms and growth during follow-up, he added.

Traditionally, TB is divided into two distinct states: LTBI and disease. LTBI is the state where the patient is asymptomatic and Mycobacterium tuberculosis is dormant. A tuberculin skin test (TST) will produce a positive result while physical examination and chest X-ray will be normal, said Tan. Management of a patient with an infection will include either an isoniazid monotherapy for 6 months or isoniazid plus rifampicin for 3 months. Conversely, in the TB disease state, the patient is symptomatic and M.  tuberculosis is actively replicating. Similar to the infection state, TST will have a positive result but unlike the infection state, physical examination and chest X-ray will be abnormal in the disease state. Management will require a multiple drug regime, said Tan.

Nevertheless, current TB concept states that both LTBI and the TB disease states may not be the only two states, and that there is a spectrum of immunological responses to a TB infection.  The spectrum includes infection elimination by innate immunity, acquired immune response, early disease with minimal symptoms and advanced clinical TB, Tan explained.

TSTis the preferred investigation test for TB in children. It assesses the degree of hypersensitivity to tuberculin purified protein derivative and the reaction size correlates with the future risk of developing TB disease. If the reaction is bigger than 15 mm, it is unlikely to be due to previous BCG vaccination or exposure to environmental mycobacteria, he explained. More than half of infants who were given BCG at birth will have a non-reactive TST at 9 to 12 months of age. However, a negative TST does not exclude the diagnosis of TB as severe malnutrition, HIV infection, disseminated TB and immunosuppressive drugs can cause false negative results.

It is estimated that as many as one-third of people worldwide have LTBI. The lifetime risk of reactivation for LTBI is around five to 10 percent. Unfortunately, most develop TB disease within the first 5 years after initial infection and the risk increases significantly if the patient has predisposing factors. [WHO. Available at: http://www.who.int/tb/challenges/ltbi/en/. Accessed on 28 July]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Roshini Claire Anthony, 19 Sep 2016

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.

01 Apr 2016
New drug applications approved by US FDA as of 16 - 31 Mar 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Apr 2015
New drug applications approved by US FDA as of 1 – 15 April 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.